Invest in Checkpoint Therapeutics Inc on Stash
Checkpoint Therapeutics, Inc. is an immuno-oncology biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. The Company is engaged in developing a portfolio of human immuno-oncology targeted antibodies. The portfolio of antibodies that it licensed includes antibodies targeting programmed death-ligand 1 (PD-L1), glucocorticoid-induced Tumor necrosis factor receptor (TNFR) related protein (GITR) and carbonic anhydrase IX (CAIX). It focuses on developing the immuno-oncology and checkpoint inhibitor antibodies. It is developing three oral, small molecules, targeted anti-cancer agents, consisting of an inhibitor of epidermal growth factor receptor (EGFR) mutations, an inhibitor of the bromodomain and extra-terminal (BET) protein, BRD4, and an inhibitor of poly (ADP-ribose) polymerase (PARP). Its pipeline of products includes CK-101 and CK-103.
To buy fractional shares
Disclaimer: Any investment you’ve selected here, which may be available to Stash customers on the Stash platform, is intended to be used for informational purposes only, should not be relied upon as the sole basis for making any investment decision, and is not intended to be a recommendation or advice by Stash that is based on your investment time horizon and/or risk tolerance. This information should not be relied upon by the reader as research or investment advice regarding any issuer or security in particular. Investors who become Stash customers are offered investment advice and recommendations through various digital features such as Diversification Score Analysis based on what they tell us about their time horizon and risk tolerance. Investing Involves Risk.
Ticker: CKPT
Checkpoint Therapeutics Inc
$2.62
+21.86%
$
The historical performance data for individual securities quoted on this website represents past performance reported as an average annual return for a given time horizon. Historical performance over the last 5 years, for example, is simply what the average return per year (compound annual growth rate) was for the investment over the past 5 years.
CKPT Performance Breakdown
Share Price
$2.62
Today's change
-1.53%
Year to date change (YTD)
-57.33%
Dividend yield
N/A
Last dividend paid
N/A
Last dividend pay date
N/A
About CKPT
Checkpoint Therapeutics, Inc. is an immuno-oncology biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. The Company is engaged in developing a portfolio of human immuno-oncology targeted antibodies. The portfolio of antibodies that it licensed includes antibodies targeting programmed death-ligand 1 (PD-L1), glucocorticoid-induced Tumor necrosis factor receptor (TNFR) related protein (GITR) and carbonic anhydrase IX (CAIX). It focuses on developing the immuno-oncology and checkpoint inhibitor antibodies. It is developing three oral, small molecules, targeted anti-cancer agents, consisting of an inhibitor of epidermal growth factor receptor (EGFR) mutations, an inhibitor of the bromodomain and extra-terminal (BET) protein, BRD4, and an inhibitor of poly (ADP-ribose) polymerase (PARP). Its pipeline of products includes CK-101 and CK-103.
Checkpoint Therapeutics Inc Stock Ticker
CKPT
For more information
The historical performance data for individual securities quoted on this website represents past performance reported as an average annual return for a given time horizon. Historical performance over the last 5 years, for example, is simply what the average return per year (compound annual growth rate) was for the investment over the past 5 years.
Invest in Checkpoint Therapeutics Inc on Stash
Checkpoint Therapeutics, Inc. is an immuno-oncology biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. The Company is engaged in developing a portfolio of human immuno-oncology targeted antibodies. The portfolio of antibodies that it licensed includes antibodies targeting programmed death-ligand 1 (PD-L1), glucocorticoid-induced Tumor necrosis factor receptor (TNFR) related protein (GITR) and carbonic anhydrase IX (CAIX). It focuses on developing the immuno-oncology and checkpoint inhibitor antibodies. It is developing three oral, small molecules, targeted anti-cancer agents, consisting of an inhibitor of epidermal growth factor receptor (EGFR) mutations, an inhibitor of the bromodomain and extra-terminal (BET) protein, BRD4, and an inhibitor of poly (ADP-ribose) polymerase (PARP). Its pipeline of products includes CK-101 and CK-103.
To buy fractional shares
Disclaimer: Any investment you’ve selected here, which may be available to Stash customers on the Stash platform, is intended to be used for informational purposes only, should not be relied upon as the sole basis for making any investment decision, and is not intended to be a recommendation or advice by Stash that is based on your investment time horizon and/or risk tolerance. This information should not be relied upon by the reader as research or investment advice regarding any issuer or security in particular. Investors who become Stash customers are offered investment advice and recommendations through various digital features such as Diversification Score Analysis based on what they tell us about their time horizon and risk tolerance. Investing Involves Risk.
Certain companies are volatile.
Certain companies can be volatile, meaning the stock price fluctuates significantly. Don’t put all your eggs into one basket and remember to keep the Stash Way in mind when you invest.
Checkpoint Therapeutics Inc stock news
This site provides links to other third-party internet sites, which are identified, indexed and compiled through an automated process with no advance review by Stash. By directing users to the below third-party websites, Stash is not suggesting any endorsement, relationship, affiliation with any such websites.
Why invest with Stash?
Fractional shares
Thousands of stocks and ETFs. No investing minimums.
Unlimited trades
Plus no add-on trading commission fees.†
Diversification analysis
Custom investment recommendations can help you diversify.
Automatic investing
Dividend reinvestment,8 recurring investments, and more.
The Stock-Back® Card
We’ll give you matching stock in companies you shop at.1
Learn how to invest
Get professional advice and education at every step.
How to buy Checkpoint Therapeutics Inc stock on Stash
Stash allows you to purchase smaller, more affordable pieces of investments (called fractional shares) rather than the whole share, which can be significantly more expensive.
Stash offers two subscription plans: Stash Growth and Stash+.
Once your market order of Checkpoint Therapeutics Inc stock is complete, you'll officially be a shareholder of Checkpoint Therapeutics Inc!
Invest in Checkpoint Therapeutics Inc on Stash
Checkpoint Therapeutics, Inc. is an immuno-oncology biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. The Company is engaged in developing a portfolio of human immuno-oncology targeted antibodies. The portfolio of antibodies that it licensed includes antibodies targeting programmed death-ligand 1 (PD-L1), glucocorticoid-induced Tumor necrosis factor receptor (TNFR) related protein (GITR) and carbonic anhydrase IX (CAIX). It focuses on developing the immuno-oncology and checkpoint inhibitor antibodies. It is developing three oral, small molecules, targeted anti-cancer agents, consisting of an inhibitor of epidermal growth factor receptor (EGFR) mutations, an inhibitor of the bromodomain and extra-terminal (BET) protein, BRD4, and an inhibitor of poly (ADP-ribose) polymerase (PARP). Its pipeline of products includes CK-101 and CK-103.
To buy fractional shares
Disclaimer: Any investment you’ve selected here, which may be available to Stash customers on the Stash platform, is intended to be used for informational purposes only, should not be relied upon as the sole basis for making any investment decision, and is not intended to be a recommendation or advice by Stash that is based on your investment time horizon and/or risk tolerance. This information should not be relied upon by the reader as research or investment advice regarding any issuer or security in particular. Investors who become Stash customers are offered investment advice and recommendations through various digital features such as Diversification Score Analysis based on what they tell us about their time horizon and risk tolerance. Investing Involves Risk.
Stash resources for confident investing
How to Start Investing
Investing in Fractional Shares on Stash
Good news: Learn how fractional shares can make an investment a lot more affordable.
Here’s How to Research Stocks
Consider P/E ratio, profit and loss, and news when buying stocks.
Subscribe to The Wallet!
Looking for financial guidance? Check your Wallet. Every week, your inbox will be packed with market savviness and clever money management techniques. Sign up today!
By using this website you agree to our Terms of Use and Privacy Policy.
More Health Care stocks
Ready to start
building wealth?